Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.32 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | PRCP | P42785 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293292 | 0.76 | HTR2B (0.42) | RIPK1SCD5PRCPHCRTR1HCRTR2 | |
| SCHEMBL934063 | 0.76 | HTR2B (0.42) | RIPK1SCD5PRCPHCRTR1HCRTR2 | |
| SCHEMBL3852873 | 0.74 | RIPK1 (0.33) | RIPK1SCD5SCDPRCPHCRTR1 | |
| SCHEMBL5314180 | 0.74 | RIPK1 (0.33) | RIPK1SCD5SCDPRCPHCRTR1 | |
| SCHEMBL28088731 | 0.74 | HCRTR1 (0.35) | RIPK1SCD5SCDPRCPHCRTR1 | |
| SCHEMBL14857164 | 0.74 | RIPK1 (0.34) | RIPK1SCDPRCPHCRTR1HCRTR2 | |
| SCHEMBL750549 | 0.74 | HCRTR1 (0.35) | RIPK1SCD5SCDPRCPHCRTR1 | |
| SCHEMBL13505827 | 0.74 | RIPK1 (0.37) | RIPK1SCDPRCPHCRTR1HCRTR2 | |
| SCHEMBL18815628 | 0.71 | PRCP (0.42) | RIPK1SCD5SCDPRCPHCRTR1 | |
| SCHEMBL18815625 | 0.71 | PRCP (0.42) | RIPK1SCD5SCDPRCPHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166586-B2 | Sulfonamide lactam inhibitors of FXa and method | BRISTOL MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | O'CONNOR STEPHEN P (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1358178-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | Bristol-Myers Squibb Company (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6555542-B1 | Factor Xa (FXa); useful as anticoagulants in the treatment of cardiovascular diseases associated with thrombosis | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-29 | — | — | US | disclosed |
| WO-2002060894-A2 | SULFONAMIDE LACTAM INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186134-A1 | Sulfonamide lactam inhibitors of FXa and method | STS, SULT1E1, F8 | RIPK1 1193/4885SCD5 695/4885SCD 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.